DIVIANNA Pharma is an emerging pharmaceutical company we are committed for enhancing people’s lives through affordable and high-quality medicines.
DIVIANNA Pharmaceuticals has a diversified product portfolio that includes medications for various therapeutic areas such as Paediatrician ,Orthopaedic Rheumatology, cardiology, neurology, and Gynaecology diseases. The company also want strong presence in the nutraceutical’s segments.
Our products are manufactured at WHO-GMP, JAS-ANZ, FDA, IAF & ISO certified facilities to provide the best quality products. under the technical support and guidance of (business partners) at multiple Manufacturing plants in India
Company Details
- Employees
- 3
- Founded
- -
- Address
- Mumbai, In
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.diviannapharma.com/
- Keywords
- Paediatrician, Rheumatology, Orthopaedic, General segment, CNS, Cardiology, Gynecology, Dentist, ENT.
- HQ
- mumbai
Divianna Pharmaceuticals Pvt Ltd Questions
Divianna Pharmaceuticals Pvt Ltd's website is https://www.diviannapharma.com/
Divianna Pharmaceuticals Pvt Ltd's LinkedIn profile is https://in.linkedin.com/company/divianna-pharmaceuticals-pvt-ltd
Divianna Pharmaceuticals Pvt Ltd has
3 employees.
View email and phone details for 3
employees at Divianna Pharmaceuticals Pvt Ltd.
Divianna Pharmaceuticals Pvt Ltd's industry is
Pharmaceutical Manufacturing
Divianna Pharmaceuticals Pvt Ltd's top competitors are
Isera Biological Pvt Ltd,
Synergy Meditech,
Raptim Research Pvt. Ltd.,
Acpc Healthcare Pvt Ltd,
Galpha Laboratories Limited,
Merck Healthcare,
Ajanta Pharma Ltd,
Aquigen Bio Science Pvt Ltd,
Sparge Chem Pvt.ltd,
Watermass Systems Pvt. Ltd..
Divianna Pharmaceuticals Pvt Ltd's categories are Pharmaceutical Manufacturing
Divianna Pharmaceuticals Pvt Ltd's founding year is 2024
